
Opinion|Videos|August 14, 2024
ESA-Ineligible LR MDS patient with Transfusion-Dependent Anemia
Author(s)Abdulraheem Yacoub, MD
Advertisement
Episodes in this series

Now Playing
Clinical Presentation:
74-year-old man diagnosed 6 months ago with LR-MDS with low-moderate anemia (Hb 11.4 g/dL)
Non-del(5q)
No family history of cancer or significant genotoxic agent exposure
Serum EPO – 550m U/L, Ring sideroblast (RS) negative
Hgb: 10.2 g/dL.
WBC and ANC: WNL
IPSS-R: Low
Received 2-3 units of blood every month for 4 months.
Treatment with ESAs is not an option due to his high serum EPO.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
2
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
3
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
4
Illuminating the Sequence of Third-Line Therapies in Metastatic CRC
5








































